Jul 10, 2018 7:30am EDT ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference
Jun 26, 2018 7:30am EDT ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Jun 20, 2018 7:30am EDT ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting
Jun 12, 2018 7:30am EDT ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease
Apr 10, 2018 7:30am EDT ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease
Apr 03, 2018 7:30am EDT ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing